Targeting of alpha-V integrins reduces malignancy of bladder carcinoma

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Van Der Horst, Geertje ^a   Bos, Lieke ^a   Van Der Mark, Maaike ^a   Cheung, Henry ^a   Heckmann, Bertrand ^b   Clément Lacroix, Philippe ^b   Lorenzon, Giocondo ^b   Pelger, Rob C M ^a   Bevers, Rob F M ^a   Van Der Pluijm, Gabri ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Galapagos SASU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; BMI1 PROTEIN; CD51 ANTIGEN; GLPG 0187; NERVE CELL ADHESION MOLECULE; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SLUG; UNCLASSIFIED DRUG; VIMENTIN; ALPHAVBETA5 INTEGRIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TUMOR PROTEIN; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BLADDER CANCER CELL LINE; BLADDER CARCINOMA; BMI1 GENE; BONE METASTASIS; CANCER GROWTH; CANCER INHIBITION; CANCER STEM CELL; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOG GENE; NONHUMAN; PLASTICITY; PROTEIN FUNCTION; PROTEIN TARGETING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLADDER TUMOR; CANCER TRANSPLANTATION; CELL ADHESION; CELL MOTION; CELL SELF-RENEWAL; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SCREENING; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEART; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PAPILLOMA; PATHOLOGY; PHARMACOLOGY; PHYSIOLOGY; PROCEDURES; RNA INTERFERENCE; TIBIA; TRANSITIONAL CELL CARCINOMA; TUMOR CELL LINE; TUMOR INVASION;

ALDEHYDE DEHYDROGENASE; ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SELF RENEWAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HEART; HUMANS; INTEGRIN ALPHAV; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PAPILLOMA; RECEPTORS, VITRONECTIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; TIBIA; TRANSCRIPTION FACTORS; TRANSDUCTION, GENETIC; TUMOR STEM CELL ASSAY; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907588664     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108464     Document Type: Article

References (56)

1. Coghlin C, Murray GI (2010) Current and emerging concepts in tumour metastasis. J Pathol 222: 1-15.
2. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
3. van der Pluijm G (2010) Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 48(1): 37-43.
4. Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273.
5. Bonnomet A, Brysse A, Tachsidis A, Waltham M, Thompson EW, et al. (2010) Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia 15: 261-273.
6. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, et al. (2006) Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 66: 11271-11278.
7. Gupta PB, Chaffer CL, Weinberg RA (2009) Cancer stem cells: mirage or reality? Nat Med 15: 1010-1012.
8. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al (2008) The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
9. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, et al. (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3: e2888.
10. Elshamy WM, Duhe RJ (2013) Overview: cellular plasticity, cancer stem cells and metastasis. Cancer Lett 341: 2-8.
11. Chang JT, Mani SA (2013) Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition. Cancer Lett 341: 16-23.
12. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
13. Alison MR, Lim SM, Nicholson LJ (2011) Cancer stem cells: problems for therapy? J Pathol 223: 147-161.
14. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 5: 744-749.
15. Bentivegna A, Conconi D, Panzeri E, Sala E, Bovo G, et al. (2010) Biological heterogeneity of putative bladder cancer stem-like cell populations from human bladder transitional cell carcinoma samples. Cancer Sci 101: 416-424.
16. He X, Marchionni L, Hansel DE, Yu W, Sood A, et al (2009) Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells 27: 1487-1495.
17. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, et al. (2009) Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A 106: 14016-14021.
18. She JJ, Zhang PG, Wang ZM, Gan WM, Che XM (2008) Identification of side population cells from bladder cancer cells by DyeCycle Violet staining. Cancer Biol Ther 7: 1663-1668.
19. Ning ZF, Huang YJ, Lin TX, Zhou YX, Jiang C, et al. (2009) Subpopulations of stem-like cells in side population cells from the human bladder transitional cell cancer cell line T24. J Int Med Res 37: 621-630.
20. Oates JE, Grey BR, Addla SK, Samuel JD, Hart CA, et al. (2009) Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. Stem Cells Dev 18: 1515-1522.
21. van der Horst G, Bos L, van der Pluijm G (2012) Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol Cancer Res 10: 995-1009.
22. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, et al (2007) ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell 1: 555-567.
23. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, et al. (2012) Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer 130: 29-39.
24. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, et al. (2010) High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 70: 5163-5173.
25. Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, et al. (2010) Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev 19: 327-337.
26. Nemeth JA, Nakada MT, Trikha M, Lang Z, Gordon MS, et al. (2007) Alpha-v integrins as therapeutic targets in oncology. Cancer Invest 25: 632-646.
27. van der Horst G, van den Hoogen C, Buijs JT, Cheung H, Bloys H, et al. (2011) Targeting of alpha(v)-Integrins in Stem/Progenitor Cells and Supportive Microenvironment Impairs Bone Metastasis in Human Prostate Cancer. Neoplasia 13: 516-525.
28. Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, et al. (2007) Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 67: 5821-5830.
29. Chen Q, Manning CD, Millar H, McCabe FL, Ferrante C, et al. (2008) CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin Exp Metastasis 25: 139-148.
30. Trikha M, Zhou Z, Nemeth JA, Chen Q, Sharp C, et al. (2004) CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 110(3): 326-335.
31. O'Day SJ, Pavlick AC, Albertini MR, Hamid O, Schalch H, et al. (2011) Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma. Invest New Drugs 30(3): 1074-1081.
32. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC, et al. (2011) Integrin alphav expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer. Am J Pathol 179: 2559-2568.
33. Sachs MD, Rauen KA, Ramamurthy M, Dodson JL, De Marzo AM, et al. (2002) Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology 60: 531-536.
34. van der Horst G, van Asten JJ, Figdor A, van den Hoogen C, Cheung H, et al. (2011) Real-Time Cancer Cell Tracking by Bioluminescence in a Preclinical Model of Human Bladder Cancer Growth and Metastasis. Eur Urol 60: 337-43.
35. Bisson I, Prowse DM (2009) WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 19: 683-697.
36. Overdevest JB, Thomas S, Kristiansen G, Hansel DE, Smith SC, et al. (2011) CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res 71: 3802-3811.
37. Hong H, Yang Y, Zhang Y, Cai W (2010) Non-invasive cell tracking in cancer and cancer therapy. Curr Top Med Chem 10: 1237-1248.
38. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
39. Marshall JF, Hart IR (1996) The role of alpha v-integrins in tumour progression and metastasis. Semin Cancer Biol 7: 129-138.
40. Guo W, Giancotti FG (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5: 816-826.
41. Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2: 91-100.
42. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
43. Yu Q, Zhang K, Wang X, Liu X, Zhang Z (2010) Expression of transcription factors snail, slug, and twist in human bladder carcinoma. J Exp Clin Cancer Res 29: 119-128.
44. Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger P, et al. (2010) The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol 28: 473-479.
45. Zhang Z, Xie D, Li X, Wong YC, Xin D, et al. (2007) Significance of TWIST expression and its association with E-cadherin in bladder cancer. Hum Pathol 38: 598-606.
46. Fondrevelle ME, Kantelip B, Reiter RE, Chopin DK, Thiery JP, et al. (2009) The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urol Oncol 27: 268-276.
47. Wang X, Zhang K, Sun L, Liu J, Lu H (2010) Short interfering RNA directed against Slug blocks tumor growth, metastasis formation, and vascular leakage in bladder cancer. Med Oncol Suppl 1: S413-422.
48. Floor S, van Staveren WC, Larsimont D, Dumont JE, Maenhaut C (2011) Cancer cells in epithelial-to-mesenchymal transition and tumor-propagatingcancer stem cells: distinct, overlapping or same populations. Oncogene 30: 4609-4621.
49. Kong D, Li Y, Wang Z, Sarkar FH (2011) Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? Cancers (Basel) 3: 716-729.
50. Cavaleri F, Scholer HR (2003) Nanog: a new recruit to the embryonic stem cell orchestra. Cell 113: 551-552.
51. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, et al. (2003) The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113: 631-642.
52. Chambers I, Colby D, Robertson M, Nichols J, Lee S, et al. (2003) Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113: 643-655.
53. Niwa H, Miyazaki J, Smith AG (2000) Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24: 372-376.
54. Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR (2007) OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 120: 1598-1602.
55. Huang P, Chen J, Wang L, Na Y, Kaku H, et al. (2012) Implications of transcriptional factor, OCT-4, in human bladder malignancy and tumor recurrence. Med Oncol 29(2): 829-834.
56. Chang CC, Shieh GS, Wu P, Lin CC, Shiau AL, et al. (2008) Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells. Cancer Res 68: 6281-6291.